Atopic Dermatitis Market Report 2026

Atopic Dermatitis Market Overview

• Atopic Dermatitis market size has reached to $9.88 billion in 2025 • Expected to grow to $19.53 billion in 2030 at a compound annual growth rate (CAGR) of 14.6% • Growth Driver: Increasing Demand For Personalized Medicine Drives The Atopic Dermatitis Market • Market Trend: Adoption Of Targeted IL-31 Receptor Antagonists In Atopic Dermatitis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Atopic Dermatitis Market?

Atopic dermatitis is a dermatological condition that causes dryness and itching of the skin. It is a chronic condition that progresses over time and is not spread by contact. The main drug classes to treat atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids refer to anti-inflammatory drugs that resemble cortisol and are used to treat a variety of diseases such as rheumatological diseases, rheumatoid arthritis, lupus, and atopic dermatitis. These are delivered through various modes of administration, including topical, injectable, and oral, and sold through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Atopic Dermatitis Market Growth Forecast?

The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $19.53 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of biologics and JAK inhibitors, rising focus on personalized dermatology treatments, expansion of injectable therapy options, growing investment in dermatology research, increasing demand for long-term symptom control. Major trends in the forecast period include increasing adoption of biologic therapies, rising demand for targeted immunomodulators, growing focus on long-term disease management, expansion of advanced topical formulations, enhanced emphasis on patient-centric treatment.

Global Atopic Dermatitis Market Segmentation

1) By Drug Class: Corticosteroids, Emollients Or Moisturizers, IL-4 And PDE4 Inhibitors, Calcineurin Inhibitors, Other Drug Classes 2) By Mode of Administration: Topical, Injectable, Oral 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids 2) By Emollients Or Moisturizers: Creams and Lotions, Ointments and Balms, Barrier Repair Creams 3) By IL-4 And PDE4 Inhibitors: Dupilumab (IL-4 Inhibitor), Apremilast (PDE4 Inhibitor) 4) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream 5) By Other Drug Classes: Biologics, JAK Inhibitors

What Is The Driver Of The Atopic Dermatitis Market?

The increasing demand for personalized medicine is expected to propel the growth of the atopic dermatitis market going forward. Personalized medicine refers to an innovative approach to medical treatment and healthcare that tailors medical decisions, practices, interventions, and drug therapies to the individual patient. Personalized medicine in atopic dermatitis involves the identification of specific genetic and molecular factors influencing the disease, enabling the development of targeted therapies that address the unique characteristics of each patient. This approach not only enhances treatment efficacy but also minimizes adverse effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group for tailored medical treatments, said the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the atopic dermatitis industry.

Key Players In The Global Atopic Dermatitis Market

Major companies operating in the atopic dermatitis market are Sanofi SA, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Allergan PLC, Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited

Global Atopic Dermatitis Market Trends and Insights

Major companies are operating in the atopic dermatitis market focusing on developing innovative therapies such as IL-31 receptor antagonists to address chronic itch, improve skin symptom control, and reduce systemic side effects compared to traditional corticosteroids or immunosuppressants. An IL-31 receptor antagonist works by blocking the IL-31 signaling pathway, which is directly involved in itch sensation and inflammation, offering a more targeted approach than broad immune suppression. For instance, in December 2024, Galderma, a Switzerland-based dermatology company, received FDA approval for Nemluvio (nemolizumab), the first monoclonal antibody that specifically targets the IL-31 receptor alpha to inhibit IL-31 signaling in moderate-to-severe atopic dermatitis. The therapy is administered via subcutaneous injection, binds to the IL-31 receptor to prevent activation by the IL-31 cytokine, and has been shown in clinical trials to provide rapid relief from itch and meaningful improvement in skin symptoms when used alongside topical treatments.

What Are Latest Mergers And Acquisitions In The Atopic Dermatitis Market?

In September 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for up to US$ 1.2 billion. Through this acquisition, Organon aims to expand its dermatology and immune-mediated skin disease portfolio by integrating Dermavant’s VTAMA® (tapinarof) cream and advancing its development for atopic dermatitis in adults and children. Dermavant Sciences Ltd. is a U.S.-based immuno-dermatology company that provides VTAMA® (tapinarof) cream, a once-daily, non-steroidal topical therapy targeting immune-mediated skin conditions.

Regional Outlook

North America was the largest region in the atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Atopic Dermatitis Market?

The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Atopic Dermatitis Market Report 2026?

The atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.